These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 31725045)

  • 1. Survival outcomes of adjuvant chemotherapy with modified weekly nab-paclitaxel and carboplatin for completely resected nonsmall cell lung cancer: FAST-nab.
    Marushima H; Kimura H; Miyazawa T; Sakai H; Furuya N; Koji K; Nakamura H; Saji H
    Anticancer Drugs; 2020 Feb; 31(2):177-182. PubMed ID: 31725045
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Feasibility study of adjuvant chemotherapy with modified weekly nab-paclitaxel and carboplatin for completely resected non-small-cell lung cancer: FAST-nab.
    Saji H; Marushima H; Miyazawa T; Sakai H; Kimura H; Kurimoto N; Nakamura H
    Anticancer Drugs; 2017 Aug; 28(7):795-800. PubMed ID: 28538017
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized phase II trial of adjuvant chemotherapy with docetaxel plus cisplatin versus paclitaxel plus carboplatin in patients with completely resected non-small cell lung cancer: TORG 0503.
    Kubota K; Kunitoh H; Seto T; Shimada N; Tsuboi M; Ohhira T; Okamoto H; Masuda N; Maruyama R; Shibuya M; Watanabe K
    Lung Cancer; 2020 Mar; 141():32-36. PubMed ID: 31931444
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups.
    Strauss GM; Herndon JE; Maddaus MA; Johnstone DW; Johnson EA; Harpole DH; Gillenwater HH; Watson DM; Sugarbaker DJ; Schilsky RL; Vokes EE; Green MR
    J Clin Oncol; 2008 Nov; 26(31):5043-51. PubMed ID: 18809614
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A retrospective comparison of adjuvant chemotherapeutic regimens for non-small cell lung cancer (NSCLC): paclitaxel plus carboplatin versus vinorelbine plus cisplatin.
    Chang WJ; Sun JM; Lee JY; Ahn JS; Ahn MJ; Park K
    Lung Cancer; 2014 Apr; 84(1):51-5. PubMed ID: 24521819
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A feasibility study of postoperative adjuvant therapy of carboplatin and weekly paclitaxel for completely resected non-small cell lung cancer.
    Yamashita Y; Kataoka K; Ishida T; Matsuura M; Seno N; Mukaida H; Miyahara E; Miyata Y; Okita R; Shimizu K; Watari M; Okumichi T; Okada M
    J Thorac Oncol; 2008 Jun; 3(6):612-6. PubMed ID: 18520800
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Multicenter Randomized Controlled Study of Paclitaxel plus Carboplatin versus Oral Uracil-Tegafur as the Adjuvant Chemotherapy in Resected Non-Small Cell Lung Cancer.
    Toyooka S; Okumura N; Nakamura H; Nakata M; Yamashita M; Tada H; Kajiwara S; Watanabe N; Okada M; Sakamoto J; Aoe M; Soh J; Miyoshi S; Hotta K; Matsuo K; Date H
    J Thorac Oncol; 2018 May; 13(5):699-706. PubMed ID: 29505900
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Paclitaxel and carboplatin adjuvant therapy alone or with radiotherapy for resected nonsmall cell lung carcinoma: a feasibility study of the Minnie Pearl Cancer Research Network.
    Greco FA; Burris HA; Gray JR; Raefsky EL; Dobbs C; Smith S; Rinaldi D; Morrissey LH; Erland JB; Litchy S; Hainsworth JD
    Cancer; 2001 Oct; 92(8):2142-7. PubMed ID: 11596031
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase II study of nab-paclitaxel and carboplatin chemotherapy plus necitumumab in the first-line treatment of patients with stage IV squamous non-small cell lung cancer.
    Villaruz LC; Cobo M; Syrigos K; Mavroudis D; Zhang W; Kim JS; Socinski MA
    Lung Cancer; 2019 Oct; 136():52-56. PubMed ID: 31445354
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvant carboplatin-based chemotherapy in resected stage IIIA-N2 non-small cell lung cancer.
    Ou W; Sun HB; Ye X; Zhang BB; Yang H; Fang Q; Li P; Wang SY
    J Thorac Oncol; 2010 Jul; 5(7):1033-41. PubMed ID: 20502361
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A dose finding study of weekly and every-3-week nab-Paclitaxel followed by carboplatin as first-line therapy in patients with advanced non-small cell lung cancer.
    Socinski MA; Manikhas GM; Stroyakovsky DL; Makhson AN; Cheporov SV; Orlov SV; Yablonsky PK; Bhar P; Iglesias J
    J Thorac Oncol; 2010 Jun; 5(6):852-61. PubMed ID: 20521351
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant chemotherapy for early-stage non-small-cell lung cancer. Single-centre experience and literature review.
    Custodio Carretero AB; García Sáenz JA; González Larriba JL; Bobokova J; Calles Blanco A; Hernando Trancho F; García Paredes B; Rodríguez Lajusticia L; Díaz-Rubio García E
    Clin Transl Oncol; 2008 Sep; 10(9):560-71. PubMed ID: 18796373
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A pilot study of adjuvant chemotherapy with carboplatin and oral S-1 for patients with completely resected stage II to IIIA non-small cell lung cancer.
    Tanaka H; Tabe C; Okumura F; Shiratori T; Ishioka Y; Itoga M; Taima K; Morimoto T; Kimura D; Tsushima T; Tasaka S
    Thorac Cancer; 2020 Jun; 11(6):1633-1638. PubMed ID: 32351044
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase II study of concurrent carboplatin and paclitaxel and thoracic radiotherapy for completely resected stage II and IIIA non-small cell lung cancer.
    Feigenberg SJ; Hanlon AL; Langer C; Goldberg M; Nicolaou N; Millenson M; Coia LR; Lanciano R; Movsas B
    J Thorac Oncol; 2007 Apr; 2(4):287-92. PubMed ID: 17409799
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II trial of nanoparticle albumin-bound paclitaxel, carboplatin, and bevacizumab in first-line patients with advanced nonsquamous non-small cell lung cancer.
    Reynolds C; Barrera D; Jotte R; Spira AI; Weissman C; Boehm KA; Pritchard S; Asmar L
    J Thorac Oncol; 2009 Dec; 4(12):1537-43. PubMed ID: 19887966
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of pathological stage and histological subtype on clinical outcome of adjuvant chemotherapy of paclitaxel plus carboplatin versus oral uracil-tegafur for non-small cell lung cancer: subanalysis of SLCG0401 trial.
    Soh J; Toyooka S; Okumura N; Nakamura H; Nakata M; Yamashita M; Sakamoto J; Aoe M; Hotta K; Morita S; Date H
    Int J Clin Oncol; 2019 Nov; 24(11):1367-1376. PubMed ID: 31312931
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nanoparticle Albumin-bound Paclitaxel Plus Carboplatin Induction Followed by Nanoparticle Albumin-bound Paclitaxel Maintenance in Squamous Non-Small-cell Lung Cancer (ABOUND.sqm): A Phase III Randomized Clinical Trial.
    Spigel DR; Jotte RM; Aix SP; Gressot L; Morgensztern D; McCleod M; Socinski MA; Daniel D; Juan-Vidal O; Mileham KF; West H; Page R; Reinmuth N; Knoble J; Chen T; Bhore R; Wolfsteiner M; Ong TJ; Gridelli C; Thomas M;
    Clin Lung Cancer; 2021 Jan; 22(1):6-15.e4. PubMed ID: 33097414
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes in 36 Patients with Stage IIIA-N2 Squamous Cell Carcinoma of the Lung Treated with Nab-Paclitaxel Plus Carboplatin as Neoadjuvant Therapy: A Prospective Study from a Single Center.
    Zhu J; Zhang Y; Wang M; Zhang Z; Yue D; Liu S; Pan Y; Wang C
    Med Sci Monit; 2021 Aug; 27():e930738. PubMed ID: 34376631
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II study of nab-paclitaxel + carboplatin for patients with non-small-cell lung cancer and interstitial lung disease.
    Kenmotsu H; Yoh K; Mori K; Ono A; Baba T; Fujiwara Y; Yamaguchi O; Ko R; Okamoto H; Yamamoto N; Ninomiya T; Ogura T; Kato T
    Cancer Sci; 2019 Dec; 110(12):3738-3745. PubMed ID: 31608537
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II Study of Modified Carboplatin Plus Weekly Nab-Paclitaxel in Elderly Patients with Non-Small Cell Lung Cancer: North Japan Lung Cancer Study Group Trial 1301.
    Miyauchi E; Inoue A; Usui K; Sugawara S; Maemondo M; Saito H; Fujita Y; Kato T; Suzuki T; Harada T; Watanabe H; Nakagawa T; Ichinose M
    Oncologist; 2017 Jun; 22(6):640-e59. PubMed ID: 28526722
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.